Feature | SCAI | May 08, 2019

Late-breaking Interventional Cardiology Presentations at SCAI 2019

Here is the list of featured clinical research at the Society for Cardiovascular Angiography and Interventions annual meeting

Khaldoon Alaswad, M.D., FSCAI, right, during a chronic total occlusion (CTO) case in his lab at Henry Ford Hospital, Detroit. He is presenting in several SCAI 2019 sessions.  SCAI 2019 late breaking sessions, SCAI featured research sessions.

Khaldoon Alaswad, M.D., FSCAI, right, during a chronic total occlusion (CTO) case in his lab at Henry Ford Hospital, Detroit. He is presenting in several SCAI 2019 sessions.  


May 8, 2019 — The Society for Cardiovascular Angiography and Interventions (SCAI) 2019 Scientific Sessions will take place May 19-22, 2019 at the Cosmopolitan of Las Vegas in Las Vegas, Nev. The biggest news will be from the featured clinical research sessions that highlight the latest advances in interventional cardiology. Here is at the list of sessions:

 

Featured Clinical Research, Part I 
   • A Risk Score to Predict Post-Discharge Bleeding Among Acute Coronary Syndrome Patients Undergoing Percutaneous Coronary Intervention: BRIC-ACS Study, presented by Yundai Chen.

   • AVIATOR-2: Antithrombotic Strategy Variability in Atrial Fibrillation and Obstructive Coronary Disease Revascularized with Percutaneous Coronary Intervention Registry, presented by Ridhima Goel, M.B.B.S

   • Plaque Regression and Endothelial Progenitor Cell Mobilization With Intensive Lipid Elimination Regimen (PREMIER), presented by Subhash Banerjee, M.D., FSCAI.

   • Superior Vena Caval Occlusion in Acute Decompensated Heart Failure: First-in-Human Experience, presented by Navin K. Kapur, M.D., FSCAI.

   • Improved Outcomes May Be Associated With the Use of Shock Protocols: Updates From the National Cardiogenic Shock Initiative, presented by Mir Basir, D.O.

 

Featured Clinical Research, Part II
   • A Global Registry of Fractional Flow Reserve (FFR)-Guided Management During Routine Clinical Procedures, presented by Erick Schampaert, M.D.

   • Derivation and Validation of Pd/Pa for the Assessment of Residual Ischemia Post Intervention - A Prospective All Comer Registry, presented by Abdul Hakeem, M.D., FSCAI.

   • First-in-Human Study of the Saranas Early Bird Bleed Monitoring System for the Detection of Endovascular Procedure Related Bleeding Events, presented by Philippe Genereux, M.D.

   • Impact of Intravascular Ultrasound-Guided Drug-Eluting Stent Implantation on Patients With Chronic Kidney Disease: Results From ULTIMATE Trial, presented by Junjie Zhang, M.D., FSCAI.

   • Vascular Closure Device Type Impacts Bleeding and Vascular Complications After TAVR: Results From the BRAVO 3 Randomized Trial, presented by David A. Power, MB BCh. 

 

Other SCAI 2019 News:

Cardiac Cath Lab Economics Consensus Statement Released by SCAI and ACVP

SCAI Releases New Consensus Document on Classification Stages of Cardiogenic Shock

Philips Launches IntraSight Interventional Applications Platform

Impella SmartAssist Platform Launches at SCAI

Cordis Announces U.S. Launch of Radial 360 Portfolio

For more information on these or other sessions, visit: www.scai.org/SCAI2019

 

Other Recent Late-breaking Cardiology Trials:

SCAI 2018 Late-breaking Clinical Trials

ACC 2019 Late-breaking Presentations

TCT 2018 Late-breaking Cardiovascular Clinical Trials

EuroPCR 2018 Late-breaking Trials in Interventional Cardiology

Heart Rhythm 2018 Late-breaking Studies

ACC 2019 Late-breaking Presentations

TCT 2019 Late-breaking Presentations

Late-breaking Interventional Cardiology Presentations at SCAI 2019

American Heart Association 2018 Late-breaking Trials

VIVA 2019 Late-breaking Clinical Trials

 

 

#SCAI2019  #SCAI19  #SCAI


Related Content

News | Cardiovascular Clinical Studies

April 16, 2024 — CVRx, Inc., a commercial-stage medical device company, announced today the availability of additional ...

Home April 16, 2024
Home
News | Cardiovascular Clinical Studies

April 11, 2024 — Transcatheter aortic valve replacement (TAVR) was found to bring no increased risks and was associated ...

Home April 11, 2024
Home
News | Cardiovascular Clinical Studies

April 11, 2024 — People with a buildup of fatty atherosclerotic plaque in the heart’s arteries considered at risk of ...

Home April 11, 2024
Home
News | Cardiovascular Clinical Studies

April 9, 2024 — Patients who took an angiotensin-converting enzyme (ACE) inhibitor while undergoing cancer treatment ...

Home April 09, 2024
Home
News | Cardiovascular Clinical Studies

April 9, 2024 — One of the first studies to attempt to treat early-stage heart failure in patients with Type 2 diabetes ...

Home April 09, 2024
Home
News | Cardiovascular Clinical Studies

April 9, 2024 — The investigational drug ninerafaxstat showed a good tolerability and safety profile, along with ...

Home April 09, 2024
Home
News | Cardiovascular Clinical Studies

April 9, 2024 — Administering tranexamic acid (TxA), a drug used to reduce bleeding during heart surgery, topically ...

Home April 09, 2024
Home
News | Cardiovascular Clinical Studies

April 9, 2024 — Using a web application to qualify individuals for treatment with a nonprescription statin closely ...

Home April 09, 2024
Home
News | Cardiovascular Clinical Studies

April 9, 2024 — People with a small aortic annulus, a part of the heart’s anatomy where the left ventricle meets the ...

Home April 09, 2024
Home
News | Cardiovascular Clinical Studies

April 8, 2024 — People with diabetes who had suffered a heart attack derived no clinical benefit from edetate disodium ...

Home April 08, 2024
Home
Subscribe Now